Salute e Benessere

Philips announces 5,000th Zenition mobile C-arm system installation, advancing…

Global adoption milestone underscores innovation in mobile C-arm surgical and interventional imaging, with more than 15 million patients treated in 170+ countries every yearAmsterdam, the Netherlands – Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the 5,000th installation of its Philips Zenition mobile surgery imaging system at Kolín Regional Hospital in the Czech Republic. Since its launch in 2019, Zenition has become a trusted solution...
Nasdaq GlobeNewswire
08/10/2025

Mintel Announces 2026 Global Beauty and Personal Care Predictions

The Mintel 2026 Global Beauty and Personal Care Predictions are: The Mintel 2026 Global Beauty and Personal Care Predictionsare: Metabolic Beauty Andrew McDougall, Mintel Director Beauty & Personal Care Insights, said: "The beauty industry has long played in the space where health and aesthetics overlap; but until recently, this connection was framed more as a marketing story than a scientific reality. While wellness culture and the concept of prevention have been...
PR Newswire
08/10/2025

Why Strength Training Matters for Women Over 35: Ultimate Performance (U.P.)…

The campaign comes as new analysis of more than 4,700 women who have trained with U.P. since 2020 reveals that waistlines are already in the 'at-risk' zone by their late 30s. The average waistline for new female clients aged 35-39 is 88.3cm, breaching the 88cm threshold that is recognized as a risk factor for metabolic diseases. Those risks accelerate with age. The average woman's waistline expands to 92.8cm by age 60, with average bodyfat levels climbing from 29% in under-35s, to 33.6% in their…
PR Newswire
08/10/2025

Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical with a Buy…

Dave Marver, Chief Executive Officer of ONWARD Medical, commented: “Portzamparc – BNP Paribas Group’s initiation of coverage underscores the significance of 2025 as a transformational year for ONWARD. With the ARC-EX ®System now cleared for commercial use in the U.S. and Europe, we have successfully transitioned to a commercial-stage company focused on delivering breakthrough therapies for spinal cord injury. We are also preparing to initiate a global pivotal study with our implantable...
Nasdaq GlobeNewswire
08/10/2025

Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to…

In this Phase 1 trial, 10 out of 21 patients received the highest and recommended intraperitoneal dose of 7 MBq Radspherin® after dose escalation (1, 2, 4 and 7 MBq). The final 24-month data still reports that only 1 of these 10 patients had peritoneal recurrence, and peritoneal recurrence rate remains at 10%. Two additional patients were reported with lymph node metastases outside of the peritoneum, giving an overall recurrence rate of 30%. In similar populations, approximately 55-60% of…
PR Newswire
08/10/2025

Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy…

AlphaMedix TM( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumorsAlphaMedix TMshowed prolonged and clinically meaningful benefits across PRRT-naïve and PRRT-exposed patients with unresectable or metastatic GEP-NETs, highlighting the potential of Targeted Alpha Therapy with lead-212 as a new treatment option Results will form the basis...
Nasdaq GlobeNewswire
08/10/2025

Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy…

AlphaMedix TM( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumorsAlphaMedix TMshowed prolonged and clinically meaningful benefits across PRRT-naïve and PRRT-exposed patients with unresectable or metastatic GEP-NETs, highlighting the potential of Targeted Alpha Therapy with lead-212 as a new treatment option Results will form the basis of future...
Nasdaq GlobeNewswire
08/10/2025

New Global Beauty & Wellbeing Report unveils Emotional Wellbeing as the True…

The findings reveal that beauty today is not about chasing perfection, but about feeling emotionally supported, connected, and in control. The findings reveal that beauty today is not about chasing perfection, but about feeling emotionally supported, connected, and in control. Speaking about the report, Anna Malmhake, CEO & President of Oriflame, said, "This report reaffirms what we've believed for decades: that beauty is a deeply emotional and empowering experience. "Across the...
PR Newswire
08/10/2025

AHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology…

Key Takeaways from the AHR Agonists Market Report Key Takeaways from the AHR Agonists Market Report Discover which indication is expected to grab the major AHR agonists market share @AHR Agonists Market Report Key Factors Driving the AHR Agonists Market Rising Prevalence of Autoimmune Diseases and Chronic Conditions The increasing incidence of autoimmune diseases and chronic conditions is a major catalyst for the AhR agonist market. Factors such as genetics,...
PR Newswire
07/10/2025

BIOVAXYS ANNOUNCES LIFE OFFERING

The Offering is expected to close on such date as the Company may determine and, in any event, on or before a date not later than 45 days after the date of this news release, subject to the satisfaction of certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including acceptance of the Canadian Securities Exchange. The Company intends to use the proceeds from the Offering to drive more organic pipeline growth by (1) pursuing multiple licensing…
PR Newswire
07/10/2025

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 09/30/2025100,325,22989,413,272For further information on Cellectis, please contact:Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76...
Nasdaq GlobeNewswire
07/10/2025

AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting

AAVantgarde Bio(AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced three presentations at the European Society of Gene & Cell Therapy 32 ndAnnual Meeting (ESGCT), to be held October 7-10 in Seville (Spain).At this conference, we will be presenting LUCE Phase 1/2 clinical data from our Usher1B program, KO pig model preclinical data from our Stargardt’s program and the platform development of a dual vector AAV...
Nasdaq GlobeNewswire
07/10/2025

Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025

Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 studyPresentation of digital pathology data from preclinical studies with lanifibranorDaix (France), New York City (New York, United States), October 7, 2025 - Inventiva(Euronext Paris and NASDAQ:IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic...
Nasdaq GlobeNewswire
07/10/2025

LBB Specialties Expands Partnership with Givaudan Active Beauty in the Midwest &…

Through this partnership, LBBS will collaborate with Givaudan to strengthen customer support in the Midwest and East, combining efforts to serve existing customers and reach new ones with Givaudan's world-class technologies. Through this partnership, LBBS will collaborate with Givaudan to strengthen customer support in the Midwest and East, combining efforts to serve existing customers and reach new ones with Givaudan's world-class technologies. "As a customer-focused company, we're…
PR Newswire
07/10/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from September 29th to October 03rd 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1101/10/2025FR00102591503000...
Nasdaq GlobeNewswire
07/10/2025

Ipsen - September 2025 - Monthly information relative to the total number of…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1) 30 September 202583,814,526Gross...
Nasdaq GlobeNewswire
07/10/2025

Rheumatoid Arthritis Drugs Market Size to Reach US$ 56.62 Billion by 2033 with…

Rheumatoid arthritis treatment aims to reduce inflammation, relieve pain, and preserve joint function through biologics, DMARDs, physical therapy, lifestyle changes, and sometimes surgery. Advances in drugs have improved disease control and patient quality of life. Rheumatoid arthritis treatment aims to reduce inflammation, relieve pain, and preserve joint function through biologics, DMARDs, physical therapy, lifestyle changes, and sometimes surgery. Advances in drugs have improved disease...
PR Newswire
07/10/2025

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as…

Global leaders such as Novartis, Biogen, AbbVie, AstraZeneca, Argenx, Takeda, and Sarepta Therapeutics are pioneering next-generation therapeutics. With strong regulatory backing, particularly from the U.S. FDA and Japan's PMDA, and rising investment in rare disease research, the neuromuscular therapeutics space is poised for sustained double-digit growth. Global leaders such asNovartis, Biogen, AbbVie, AstraZeneca, Argenx, Takeda, and Sarepta Therapeuticsare pioneering next-generation…
PR Newswire
07/10/2025

Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene…

Global leaders such as Roche, Novartis, Pfizer, Takeda, Sanofi, and Biogen are spearheading innovation pipelines, while emerging biotech companies are leveraging RNA technologies, CRISPR-based gene editing, and monoclonal antibodies to address unmet needs. Global leaders such asRoche, Novartis, Pfizer, Takeda, Sanofi, and Biogenare spearheading innovation pipelines, while emerging biotech companies are leveragingRNA technologies, CRISPR-based gene editing, and monoclonal antibodiesto...
PR Newswire
07/10/2025

Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in…

Primary endpoint was met in clinical study, demonstrating a comparable safety profile and a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults.Results will support filing for label extension with EMA in 2026.COPENHAGEN, Denmark, October 7, 2025– Bavarian Nordic A/S (OMX: BAVA) today reported topline results from a clinical study of its MVA-BN ®mpox/smallpox vaccine in children 2 to 11 years of age.The study ( NCT06549530 ) enrolled 460...
Nasdaq GlobeNewswire
07/10/2025

PureHealth completes EUR 800 million acquisition of Hellenic Healthcare Group…

Through the integration of HHG's 11 hospitals and 23 diagnostic centres, PureHealth will expand access to healthcare services for more than 1.4 million patients annually. With over 6,900 healthcare professionals, HHG now becomes an integral part of PureHealth's international ecosystem, reinforcing Abu Dhabi's position as a global hub for healthcare excellence and investment. Through the integration of HHG's 11 hospitals and 23 diagnostic centres, PureHealth will expand access to healthcare...
PR Newswire
07/10/2025

Melatonin Market to Reach USD 3.0 Billion by 2030 as Sleep Health, Supplements…

Global players like Pfizer, Nature's Bounty, Natrol, and BASF are actively expanding portfolios, while biotech firms in Asia, particularly China, are scaling production of synthetic and natural melatonin. Increasing clinical validation of melatonin's role in neurology, oncology, and immune health is also expanding its medical applications. Global players likePfizer, Nature's Bounty, Natrol, and BASFare actively expanding portfolios, while biotech firms inAsia, particularlyChina, are...
PR Newswire
07/10/2025

Veterinary Software Market worth US$2.14 billion by 2030 with 6.9% CAGR |…

Browse in-depth TOC on 'Veterinary Software Market'392 - Tables63 - Figures390 - Pages Browse in-depth TOC on 'Veterinary Software Market' 392 - Tables 63 - Figures 390 - Pages By practice type,the market is segmented into exclusive small animal practices, mixed animal practices, and exclusive large animal practices. Mixed animal practices are further divided into predominantly small animal practices and predominantly large animal practices. Exclusive large animal practices are...
PR Newswire
07/10/2025

Multi Cancer Early Detection Testing Market to Reach US$ 7.52 Billion by 2033 as…

Global adoption is accelerating, led by GRAIL's Galleri Test, Guardant Health's liquid biopsy platforms, and Exact Sciences' precision oncology solutions. Investments from Roche's Foundation Medicine and biotech innovators such as Burning Rock, Lucence Health, and Freenome are further shaping the competitive landscape. Global adoption is accelerating, led byGRAIL's Galleri Test, Guardant Health's liquid biopsy platforms, and Exact Sciences' precision oncology solutions.Investments from...
PR Newswire
07/10/2025
Altri  Comunicati